lotrafiban has been researched along with sk&f 107260 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, FE; Barton, LS; Bondinell, WE; Burgess, JL; Callahan, JF; Calvo, RR; Chen, L; Chen, W; Erhard, K; Feuerstein, G; Heys, R; Huffman, WF; Hwang, SM; Jakas, DR; Keenan, RM; Ku, TW; Kwon, C; Lee, CP; Miller, WH; Newlander, KA; Nichols, A; Parker, M; Peishoff, CE; Rhodes, G; Ross, S; Samanen, JM; Shu, A; Simpson, R; Takata, D; Uzsinskas, I; Venslavsky, JW; Yellin, TO; Yuan, CK | 1 |
| Gretler, DD; Scarborough, RM | 1 |
1 review(s) available for lotrafiban and sk&f 107260
| Article | Year |
|---|---|
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Design; Fibrinolytic Agents; Humans; Injections; Integrins; Molecular Mimicry; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Venoms | 2000 |
1 other study(ies) available for lotrafiban and sk&f 107260
| Article | Year |
|---|---|
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.
Topics: Administration, Oral; Benzodiazepinones; Humans; Platelet Glycoprotein GPIIb-IIIa Complex | 1996 |